TREKSTOR
Today the TREKSTOR GmbH, the manufacturer behind the blnk branded healthcare products, completed delivery of 100.000 FFP2 class respirators to the Tafel Deutschland. This is a reaction to the increased demand for certified PPE products created by both decisions of the federal government as well as the FFP2 mandate active in the state of Bavaria.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005522/en/
„As a German company, which mainly exists today due to the sales of entry-level PCs and tablets to price-sensitive customers in the past, we are aware of our responsibility to our fellow citizens“ , Shimon Szmigiel, CEO of TREKSTOR, explains. „Many of them are lagging the financial prowess to purchase high quality protective equipment, a state that is worsened by lay-offs and short-time work arrangements.”
Therefore, TREKSTOR decided on short notice to donate 50.000 packs containing 2 pcs of its own blnk brand model BL-03N FFP2 respirators, which are normally sold to government, hospital and care facilities. As do all FFP2 respirators, it filters ≥94% of particles, in the COVID-19 relevant comparison with NaCL, the masks even performed above the 99% mark.
„The selection of Tafel Deutschland as our partner was very easy“ , adds Shimon Szmigiel. This is due to existing infrastructure and experience when it comes to distributing food, which makes the Tafel to a unique distribution network. Based on the agreement, the respirators were delivery to a central warehouse in Nurnberg and will from there be distributed to the 168 locations in Bavaria according to demand.
Jochen Brühl, Chairman of Tafel Deutschland: „We are delighted for this wonderful support. People in poverty are especially affected by this crisis. As important as the mask mandate is, it is a financial burden for poor people. Around 1.6 million people rely on our food banks, among them 430.000 retirees and up to 500.000 children and youths. The donation by TREKSTOR helps them to protect themselves while also relieving some of the financial pressure. For that, we are very thankful.“
TREKSTOR is aware, that this donation is literally only a drop in the ocean, which is why Shimon Szmigiel appeals to all other businesses: “If you are active in the same areas we are – or if you are not, take heart, temporarily forget about profit, and do something good.”
About TREKSTOR / blnk Healthcare
TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies, and end-consumers.
About Tafel Deutschland e.V.
The 950 charitable food banks in Germany collect impeccable surplus food from retailers and manufacturers and distribute it regularly to more than 1.6 million poor people across the country. In doing so, they create a balance between waste and poverty. With around 60,000 volunteers who are involved in the food banks, the food banks are one of the largest socio-ecological movements in Germany. The food banks are organized in the umbrella organization Tafel Deutschland e. V.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005522/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
